NCT03213665
Clinical Trial Information
Trial Number: NCT03213665 (ClinicalTrials.gov)
Disease Type:
- CNS Neoplasm (Primary Tumor) - Miscellaneous
- CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
- Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
- Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
- Miscellaneous Neoplasm - Solid Tumor
Trial Title:
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex"
Study ID:
APEC1621C
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®